AN2 Therapeutics Inc Cash Flow-to-Debt Ratio
AN2 Therapeutics Inc cash flow-to-debt ratio. AN2 Therapeutics Inc (ANTX) has a Cash Flow-to-Debt Ratio of -1.22x as of June 2026, meaning its operating cash flow of $-7.00 Million could theoretically repay -1% of its total liabilities ($5.75 Million) in one year. See how financially flexible is AN2 Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of AN2 Therapeutics Inc (2019–2025)
Cash flow-to-debt ratio of AN2 Therapeutics Inc from 2019 to 2025. Historical debt coverage capacity for AN2 Therapeutics Inc across 7 annual periods. Also explore net asset growth rate of AN2 Therapeutics Inc to track the company's year-over-year net asset growth rate.
AN2 Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
AN2 Therapeutics Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for AN2 Therapeutics Inc. For the full cash flow conversion analysis, see AN2 Therapeutics Inc (ANTX) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.36x | $-29.83 Million | $8.89 Million | ▲ +30.2% |
| 2024 | -4.81x | $-49.26 Million | $10.24 Million | ▼ -26.8% |
| 2023 | -3.79x | $-53.29 Million | $14.04 Million | ▲ +18.5% |
| 2022 | -4.66x | $-33.46 Million | $7.19 Million | ▲ +22.5% |
| 2021 | -6.01x | $-20.48 Million | $3.41 Million | ▼ -66.2% |
| 2020 | -3.62x | $-5.36 Million | $1.48 Million | ▼ -29.1% |
| 2019 | -2.80x | $-2.49 Million | $887.00K | — |